Ipsen SA (0MH6) RNS Announcements

Add to Alert list
Date Time Source Announcement
18 Nov 2024 06:00 AM
GNW
Bylvay® (odevixibat) data shows sustained imp...
15 Nov 2024 04:00 PM
GNW
Iqirvo® (elafibranor) data shows efficacy and...
23 Oct 2024 06:00 AM
GNW
Ipsen delivers strong sales momentum in the f...
14 Oct 2024 05:00 PM
GNW
Ipsen receives its second Shingo Prize for op...
23 Sep 2024 12:13 PM
GNW
Ipsen’s Kayfanda® (odevixibat) approved in Eu...
20 Sep 2024 01:57 PM
GNW
Ipsen’s Iqirvo® (elafibranor) approved in the...
16 Sep 2024 01:45 PM
GNW
Final results from CABINET Phase III trial re...
15 Sep 2024 01:45 PM
GNW
Ipsen provides update on CONTACT-02 Phase III...
26 Jul 2024 11:46 AM
GNW
Ipsen receives CHMP positive opinions for Iqi...
25 Jul 2024 06:00 AM
GNW
Ipsen delivers strong results in the first ha...
25 Jul 2024 05:58 AM
GNW
Ipsen and Day One enter into exclusive ex-U.S...
11 Jul 2024 06:00 AM
GNW
Ipsen and Foreseen Biotechnology announce exc...
02 Jul 2024 06:00 AM
GNW
Ipsen expands collaboration and license agree...
10 Jun 2024 09:54 PM
GNW
Ipsen’s Iqirvo® receives U.S. FDA accelerated...
07 Jun 2024 06:00 AM
GNW
Ipsen and Marengo Therapeutics announce secon...
06 Jun 2024 01:30 PM
GNW
Ipsen appoints Josep Catllà as EVP, Chief Cor...
05 Jun 2024 07:00 AM
GNW
Ipsen presents long-term elafibranor efficacy...
02 May 2024 06:30 AM
GNW
Ipsen appoints Keira Driansky as EVP, Preside...
24 Apr 2024 06:00 AM
GNW
Ipsen delivers strong sales in the first quar...
22 Apr 2024 06:00 AM
GNW
Ipsen and Skyhawk Therapeutics announce RNA t...
02 Apr 2024 06:00 AM
GNW
Ipsen and Sutro Biopharma announce exclusive ...
13 Feb 2024 09:08 PM
GNW
Ipsen’s Onivyde® regimen, a potential new sta...
08 Feb 2024 05:58 AM
GNW
Building on solid FY 2023 results, Ipsen anti...
22 Jan 2024 10:00 PM
GNW
Latest Phase III trial data investigating Cab...
07 Dec 2023 06:00 AM
GNW
Ipsen confirms U.S. FDA grants priority revie...
07 Dec 2023 06:00 AM
GNW
Capital Markets Day 2023 - Ipsen outlines nex...
13 Nov 2023 09:30 PM
GNW
Results from Ipsen’s ELATIVE® pivotal Phase I...
26 Oct 2023 06:00 AM
GNW
Ipsen delivers solid sales growth in the firs...
23 Oct 2023 06:00 AM
GNW
Ipsen updates on E.U. Marketing Authorisation...
03 Oct 2023 05:00 PM
GNW
Ipsen updates on QM-1114 regulatory process
04 Sep 2023 06:00 AM
GNW
Ipsen nominates Pascal Touchon to its Board o...
01 Sep 2023 06:00 AM
GNW
Ipsen announces change in R&D leadership: How...
21 Aug 2023 06:00 AM
GNW
Exelixis and Ipsen Announce Positive Results ...
16 Aug 2023 08:32 PM
GNW
US FDA approves Ipsen’s SohonosTM (palovarote...
27 Jul 2023 06:00 AM
GNW
Ipsen delivers solid H1 2023 results and upgr...
24 Jul 2023 06:00 AM
GNW
Ipsen announces a simplification of the conce...
21 Jul 2023 01:52 PM
GNW
Correction: Ipsen provides update on E.U. Mar...
21 Jul 2023 12:52 PM
GNW
Ipsen provides update on E.U. Marketing Autho...
19 Jul 2023 05:42 PM
GNW
Ipsen announces European Commission decision ...
30 Jun 2023 06:00 AM
GNW
Ipsen and GENFIT Announce Positive Results fr...
29 Jun 2023 01:00 AM
GNW
Ipsen announces positive outcome of FDA Advis...
14 Jun 2023 09:35 PM
GNW
Correction: Ipsen announces U.S. FDA submissi...
14 Jun 2023 07:21 PM
GNW
Ipsen announces U.S. FDA submission acceptanc...
13 Jun 2023 06:10 PM
GNW
U.S. FDA approves Bylvay® for patients living...
12 Jun 2023 06:00 AM
GNW
Ipsen to present new data on clinical outcome...
UK 100

Latest directors dealings